Johnson & Johnson(JNJ)

NEW BRUNSWICK, NJPharmaceutical1 H-1B visas (FY2023)

Focus: Johnson & Johnson is a diversified pharmaceutical giant with $85.2B in annual revenue and 131,900 employees, commanding significant market share across oncology, immunology, neuroscience, cardiovascular, and infectious disease. The company maintains peak-stage blockbuster franchises but faces substantial patent cliff exposure starting in 2029.

Oncology Immunology Neuroscience Cardiovascular

Profile data last refreshed 18h ago · AI intelligence enriched 1w ago

Funding Stage

PUBLIC

Employees

131,900

Open Jobs

Recent layoff filing — 86 affected

5/1/2026 — New Brunswick, NJ · 86 affected · Layoff

Source: state DOL filings via Big Local News

About Johnson & Johnson

AI assessmentNot Hiring

No open roles listed right now. Follow Johnson & Johnson to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

6/9 — Partial

Company HealthSolid

Pipeline

Early-stage

50 total

LOE Risk

6 imminent

EDURANT

Hiring

Stable

Revenue

$85.2B

FY2025

Key Products

XARELTO

Deep vein thrombosis, pulmonary embolism

$6.3B

Peak

Flagship anticoagulant generating nearly half of company revenue; FXa inhibitor with no patent expiration date disclosed, representing core earnings engine.

Help build intelligence for Johnson & Johnson

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to world-class R&D infrastructure and proven blockbuster development capability across five major therapeutic areas with $85.2B in annual revenue backing innovation.
Stable, profitable organization with $35.2B net income (FY 2025) and $24.1B cash position providing job security and competitive compensation.
Exposure to peak-stage marketed drugs (XARELTO $6.3B Part D, INVEGA SUSTENNA $1.8B) offers insight into commercial execution and lifecycle management of mega-blockbusters.

Watch Out For

Critically low R&D intensity (1%) combined with a shallow, eclectic pipeline (20 total trials across early phases) signals limited investment in next-generation innovation relative to scale.
Three major patent cliffs beginning 2029 threaten $3.2B in revenue; recent layoffs (548 employees across 2024-2026) indicate structural cost pressures and workforce instability despite profitability.

Generated by Claude from Johnson & Johnson's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

INVEGA SUSTENNA

Schizophrenia and schizoaffective disorder

$1.8B

Peak4.5yr

Second-largest revenue contributor; long-acting antipsychotic facing patent expiration in 2031, creating near-term LOE risk.

ERLEADA

Prostate cancer

$1.1B

Peak14.4yr

Androgen receptor inhibitor in peak revenue with extended patent protection until 2041; strong oncology franchise anchor.

OPSUMIT

Pulmonary arterial hypertension

$1.0B

Peak3.2yr

Endothelin receptor antagonist contributing $1B annually but facing patent cliff in 2029, second-nearest major LOE risk.

UPTRAVI

Pulmonary arterial hypertension

$758M

Peak10.8yr

Prostacyclin receptor agonist in niche PAH indication; patent protection extends to 2037.

TREMFYA

Psoriasis

$531M

Peak

IL-23 antagonist biologic with no patent expiration disclosed; immunology franchise contributor in growing dermatology segment.

INVEGA TRINZA

Schizophrenia and schizoaffective disorder

$530M

Peak15.3yr

Extended-release formulation of INVEGA platform; patent protection extends to 2041, offering longer runway than monthly SUSTENNA.

SYMTUZA

HIV infection

$469M

Peak12.0yr

Fixed-dose HIV combination therapy; patent cliff in 2038 positions it for later-stage LOE compared to cardiovascular franchises.

INVOKANA

Type 2 diabetes

$357M

Peak3.1yr

SGLT2 inhibitor; earliest major patent expiration (2029) creates immediate LOE pressure in highly competitive diabetes market.

PREZCOBIX

HIV infection

$272M

Peak6.2yr

HIV protease inhibitor fixed-dose combination; patent cliff in 2032 reflects commoditization risk in antiretroviral market.

Pipeline & Clinical Trials

TEST LENS

Ocular Physiology

N/A

Clinical Trials (1)

NCT05502289Clinical Evaluation of Delefilcon A and Verofilcon A Daily Disposable Toric Soft Contact Lenses Over One Week of Wear

N/A

Test 8.5BC

Visual Acuity

N/A

Clinical Trials (1)

NCT03139578Short-Term Clinical Comparison of Two Silicone Hydrogel Daily Disposable Contact Lenses

N/A

Experimental - Tampon with GML

Vaginal Microflora

N/A

Clinical Trials (1)

NCT00913523Clinical Evaluation of Effects of an Investigational Tampon on Vaginal Microflora

N/A

Allergy and Asthma Following Children Who Were Fed Supplemented Infant Formula

Allergy

N/A

Clinical Trials (1)

NCT00740974Allergy and Asthma Following Children Who Were Fed Supplemented Infant Formula

N/A

etafilcon A

Visual Acuity

N/A

Clinical Trials (1)

NCT02679976Marketed Contact Lens Real World Through Focus Curve

N/A

Wash IP

Dermatitis, Atopic

N/A

Clinical Trials (1)

NCT04740892A Study of a Moisturizing Cream and Baby Wash in the Management of Mild to Moderate Atopic Dermatitis in Infants, Toddlers and Children

N/A

JJVC Investigational Multifocal Contact Lens

Visual Acuity

N/A

Clinical Trials (1)

NCT04794751Evaluation of Investigational Daily Disposable Multifocal Contact Lenses Produced With Different Manufacturing Processes

N/A

senofilcon A

Myopia

N/A

Clinical Trials (1)

NCT00975585Clinical Performance Comparison of Two Contact Lenses

N/A

Toric Multifocal etafilcon A with PVP

Visual Acuity

N/A

Clinical Trials (1)

NCT03713281Evaluation of a Toric Multifocal Contact Lens Manufactured in Etafilcon Material in a Low ADD Hyperopic Population

N/A

SPF50+

Sun Protection

N/A

Clinical Trials (1)

NCT02952235Evaluation of Sunscreens Under Actual Use Conditions

N/A

Bioequivalence Study of Patches With Different Release Profiles

Female Contraception

N/A

Clinical Trials (1)

NCT00697307Bioequivalence Study of Patches With Different Release Profiles

N/A

Dyad training

Technical Skills Training

N/A

Clinical Trials (1)

NCT02895685Group Dynamics in Surgical Skill Training

N/A

Formula PD-F-7716

Inadequate Lubrication

N/A

Clinical Trials (1)

NCT01271036Safety Study of a Sensitive Sensual Touch and Personal Lubricant

N/A

JJVC Investigational Multifocal Contact Lens

Visual Acuity

N/A

Clinical Trials (1)

NCT04615507Evaluation of a Daily Disposable Novel Multifocal Contact Lens in a Myopic Population; Part 2

N/A

Infant formula

Healthy Term Infants

N/A

Clinical Trials (1)

NCT00712608The Evaluation of Cow's Milk Formula - Study B

N/A

senofilcon A contact lenses

Ametropia

N/A

Clinical Trials (1)

NCT03319212Clinical Characterization of Symptomatic Populations

N/A

Tecnis Symfony Optiblue/Tecnis Symfony Optiblue Toric

Cataract

N/A

Clinical Trials (1)

NCT06567834Clinical Evaluation and Comparison of the Tecnis Symfony Optiblue and Tecnis Symfony IOLs

N/A

etafilcon A control lens

Refractive Ametropia

N/A

Clinical Trials (1)

NCT01484028Evaluation of the Performance of Two Contact Lenses Compared to a Marketed Lens

N/A

Fall Prevention Tool Kit prototype using a randomized design

Patient Falls

N/A

Clinical Trials (1)

NCT00675935Falls - Tailoring Interventions for Patient Safety

N/A

Marketed Contact Lens

Tear Film Characteristics

N/A

Clinical Trials (1)

NCT02760810Clinical Evaluation of An Approved Contact Lens

N/A

senofilcon A

Meibomian Gland Dysfunction

N/A

Clinical Trials (1)

NCT01819194Contact Lens Comfort Relative to Meibomian Gland Status

N/A

Professional medical interpreter

Language Discordance

N/A

Clinical Trials (1)

NCT01041014Cost Effectiveness of Language Services in Hospital Emergency Departments (EDs)

N/A

Motivational Interviewing to Address Suicidal Ideation- Revised

Suicide, Attempted

N/A

Clinical Trials (1)

NCT05256940Motivational Interviewing to Address Suicidal Ideation for Veterans at High Risk for Suicide

N/A

Model C0002

Cataracts

N/A

Clinical Trials (1)

NCT05531292PROOF-OF-CONCEPT STUDY FOR NEW INTRAOCULAR LENS, MODEL C0002

N/A

Cheetah System

Myopia

N/A

Clinical Trials (1)

NCT04200898Clinical Investigation of the Cheetah System For The Correction of Myopia With and Without Astigmatism

N/A

Education

Food Insecurity

N/A

Clinical Trials (1)

NCT02558660Evaluating Use of a Farmers Market Incentive Program Among Low-Income Health Center Patients

N/A

TEST Contact Lens

Visual Acuity

N/A

Clinical Trials (1)

NCT02756078Clinical Performance Evaluation of Two Silicone Hydrogel Lenses

N/A

Group and 1:1 occupational therapy sessions

Occupational Deprivation

N/A

Clinical Trials (1)

NCT07035210Impact of Self-directed Goals for Long-term Patients in a Forensic Hospital: A Mixed-Methods Pilot Study

N/A

Mouth Rinse 19668-012

Gingivitis

N/A

Clinical Trials (1)

NCT01821261A Clinical Trial to Test the Effect of an Experimental Mouth Rinse on Gum Disease

N/A

Cartoon video describing study information notice

Information Disclosure

N/A

Clinical Trials (1)

NCT05341791Paper Versus Cartoon Video-based Administration of Study Information Notice for Participant Consent

N/A

JJVC Investigational Multifocal Contact Lens

Visual Acuity

N/A

Clinical Trials (1)

NCT04310566Evaluation of a Daily Disposable Novel Multifocal Contact Lens in a Myopic Population

N/A

Vistakon Investigational Multi-Purpose Solution II

Contact Lens Wear

N/A

Clinical Trials (1)

NCT01055457Vistakon Investigational Multi-purpose Contact Lens Care Solution.

N/A

TRP-200

Visual Acuity

N/A

Clinical Trials (1)

NCT04885296Evaluation of Prototype Lenses With Experimental UV/HEV Blocker

N/A

alphafilcon A toric

Ametropia

N/A

Clinical Trials (1)

NCT00630305Endothelial Bleb Response With Toric Lenses

N/A

Feeback group

Adult Smokers

N/A

Clinical Trials (1)

NCT00529256Evaluation of Organisational Changes to Promote Smoking Cessation

N/A

Amino Acid formula

Cow's Milk Allergy

N/A

Clinical Trials (1)

NCT01584245Evaluation of the Efficacy of an Amino Acid Based Formula in Infants

N/A

JJVC Investigational Contact Lens

Visual Acuity

N/A

Clinical Trials (1)

NCT04287036Objective Vision Evaluation of Two Cosmetic Contact Lenses

N/A

ACUVUE OASYS 1-Day for Astigmatism

Visual Acuity

N/A

Clinical Trials (1)

NCT06649019Evaluation of Lens Rotation in Habitual Wearers of Toric, Soft Contact Lenses

N/A

Follow-up Study After Bankart Repair Using MG-1

Shoulder Dislocation

N/A

Clinical Trials (1)

NCT02228226Follow-up Study After Bankart Repair Using MG-1

N/A

Colgate® Regular Cavity Protection

Tooth Stain

N/A

Clinical Trials (1)

NCT02151058A Clinical Trial to Test the Effect of a Marketed Mouth Rinse on Stain Removal

N/A

ELITA System

Refractive Error

N/A

Clinical Trials (1)

NCT05713253A PHASED, PROSPECTIVE, MULTI-CENTER STUDY OF THE ELITA SYSTEM

N/A

Characterization of the Edge of Soft Contact Lens and Its Interaction With Ocular Surface

Healthy

N/A

Clinical Trials (1)

NCT00707291Characterization of the Edge of Soft Contact Lens and Its Interaction With Ocular Surface

N/A

INFUSE® One Day Multifocal

Visual Acuity

N/A

Clinical Trials (1)

NCT07076160Pilot Dispensing Study of Two Marketed Daily Disposable Multifocal Contact Lenses

N/A

JJVC Marketed Contact Lens

Visual Acuity

N/A

Clinical Trials (1)

NCT03431441Clinical Evaluation of 2-Week Reusable ACUVUE 2 Vivid Style

N/A

etafilcon A

Visual Acuity

N/A

Clinical Trials (1)

NCT03059810Clinical Evaluation of Investigational Multifocal Contact Lenses

N/A

Nutritional Beverage

Concentration

N/A

Clinical Trials (1)

NCT01355601Effect of Carbohydrates From Nutritional Beverages in Children

N/A

bi-planer radiography

Femoro Acetabular Impingement

N/A

Clinical Trials (1)

NCT04418596Longitudinal Follow-up of Male Soccer Players Prone to Developing CAM Hip Deformity

N/A

Vertebroplasty

Vertebral Compression Fractures

N/A

Clinical Trials (1)

NCT06670404Prospective Evaluation of Therapeutic Combination in Treating Vertebral Compression Fractures

N/A

Sunscreen A

Sunscreen

N/A

Clinical Trials (1)

NCT05565625A Study to Evaluate the Whitening Effect of Mineral Sunscreens in Multi-Cultural Skin Tones

N/A

Long-term Caloric Restriction and Cellular Aging Markers

Aging

N/A

Clinical Trials (1)

NCT01256840Long-term Caloric Restriction and Cellular Aging Markers

N/A

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Portfolio: 373 approved products, 150 clinical trials

Top TAs: Oncology, Neurology, Infectious Diseases

H-1B (2023): 1 approval

Publications: 125 in PubMed

SEC Filings: 2 available

Portfolio Health

Pre-Launch35 (9%)

Launch7 (2%)

Growth5 (1%)

Peak30 (8%)

LOE Approaching134 (36%)

Post-LOE162

Therapeutic Area Focus

Oncology

40 marketed680 pipeline

Neurology

55 marketed453 pipeline

Infectious Diseases

83 marketed185 pipeline

Immunology

27 marketed208 pipeline

Financials (FY2025)

Revenue

$85.2B6%

R&D Spend

$483M(1%)

Net Income

$35.2B

Cash

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Risk Signals

WARN Act Layoff Notices (3)

2026-05-01

86 employees affected— New Brunswick, NJ

2024-09-01

231 employees affected— New Brunswick, NJ

2024-09-01

231 employees affected— New Brunswick, NJ

Source: state DOL filings, aggregated via Big Local News

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Clinical and Diagnostic Considerations in Laryngeal Leishmaniasis: A Systematic Review.

OTO open

2026

PMID:42534512

Prevalence of substance use during pregnancy in New Jersey: Investigating the effects of the COVID-19 public health emergency.

chlorhexidine gluconate

17 marketed133 pipeline

Cardiovascular

24 marketed80 pipeline

Ophthalmology

101 pipeline

Respiratory

24 marketed66 pipeline

Three WARN filings totaling 548 employees (predominantly at New Brunswick headquarters) across 2024–2026 indicate sustained workforce optimization tied to patent cliff preparation.

Recent and ongoing layoffs at headquarters signal structural cost-cutting aligned with patent cliff hedging; job security is contingent on direct contribution to peak-revenue products or survival franchises post-2029.

Drug and alcohol dependence reports

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Johnson & Johnson(JNJ)

About Johnson & Johnson

Why Work Here

Key Products

Watch Out For

Products & Portfolio (54)

Key Products by Revenue

Other Products (25)

Pipeline & Clinical Trials

Recent News · Johnson & Johnson(10)

Open Jobs (0)

Financials (FY2025)

Hiring Trend

Visa Sponsorship

Risk Signals

WARN Act Layoff Notices (3)

Research Publications(10)